Clinical Trials

Alexion Pharmaceuticals and Complement Pharma announced a partnership to co-develop the preclinical C6 complement inhibitor CP010 for neurodegenerative disorders. C6 inhibition prevents…
Read More...

BlackThorn Therapeutics announced enrollment of the first healthy volunteers in a Phase 1 study of BTRX-335140, a kappa opioid receptor (KOR) antagonist that targets brain circuits that…
Read More...

Sensei Biotherapeutics announced the publication of data from the company’s multi-center Phase 1 clinical trial to assess safety and immunogenicity of SNS-301 (formerly PAN-301) in…
Read More...

Merck announced interim results from Cohort A of KEYNOTE-427, a Phase 2 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as first-line treatment for advanced clear cell renal cell…
Read More...

Novartis announced positive results from the third Phase III trial of Kisqali (ribociclib) in advanced or metastatic breast cancer. MONALEESA-3 showed Kisqali plus fulvestrant…
Read More...

Syndax Pharmaceuticals and Nektar Therapeutics announced a non-exclusive, clinical collaboration to evaluate the safety and efficacy of Nektar's NKTR-214, a CD122-biased agonist, in…
Read More...

A first-in-human trial evaluating an experimental treatment for Ebola virus disease has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland. The Phase 1…
Read More...

INmune Bio, Inc., an immunotherapy company developing therapies that reprogram the patient’s innate immune system to treat cancer, announced that it has initiated a Phase 1 clinical…
Read More...

Avenue Therapeutics announced that its first pivotal Phase 3 trial of IV tramadol achieved the primary endpoint of a statistically significant improvement in Sum of Pain Intensity…
Read More...

Pfizer announced positive top-line results of a Phase 3 study examining the use of LYRICA (pregabalin) Oral Solution CV as adjunctive therapy for partial onset seizures in pediatric…
Read More...

Albireo Pharma announced the first patient has been enrolled in PEDFIC-1, a Phase 3 clinical trial of lead product candidate A4250, an ileal bile acid transporter (IBAT) inhibitor being…
Read More...

Eli Lilly and Company announced that galcanezumab met its primary endpoint in a Phase 3 study of patients with episodic cluster headache, demonstrating statistically significant…
Read More...

UCB announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the company’s newest anti-epileptic drug (AED) BRIVIACT …
Read More...

Novartis announced that the US Food and Drug Administration (FDA) has approved Gilenya (fingolimod) for the treatment of children and adolescents 10 to less than 18 years of age with…
Read More...

VBI Vaccines announced positive final top-line results from the randomized, placebo-controlled Phase 1 study of VBI-1501, the company’s prophylactic cytomegalovirus (CMV) vaccine…
Read More...

miRagen Therapeutics announced new interim data from its Phase 1 clinical trial of cobomarsen in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL). The…
Read More...

Sylentis, Pharmaceutical Company belonging to the PharmaMar Group, has presented results from the clinical studies carried out with tivanisiran for the treatment of dry eye syndrome and…
Read More...

MenoGeniX announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant for…
Read More...

Cirius Therapeutics announced that it has reached its enrollment target in its Phase 2b EMMINENCE trial for its lead program MSDC-0602K in more than 380 patients with NASH and liver…
Read More...

Bioniz Therapeutics announced top-line results from its multiple ascending dose Phase 1b clinical trial of BNZ-1, a novel multi-cytokine inhibitor targeting interleukin (IL)-2, IL-9,…
Read More...